We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial.
- Authors
MacLennan JM; Shackley F; Heath PT; Deeks JJ; Flamank C; Herbert M; Griffiths H; Hatzmann E; Goilav C; Moxon ER; MacLennan, J M; Shackley, F; Heath, P T; Deeks, J J; Flamank, C; Herbert, M; Griffiths, H; Hatzmann, E; Goilav, C; Moxon, E R
- Abstract
<bold>Context: </bold>Neisseria meningitidis is a common cause of meningitis and septicemia in infants worldwide. Whether a meningococcal C conjugate vaccine protects infants against the serogroup C strain is unknown.<bold>Objectives: </bold>To determine whether a meningococcal C conjugate vaccine is safe and immunogenic and induces immunologic memory in infants.<bold>Design: </bold>Single-center, double-blind, randomized controlled trial in 1995 and 1996.<bold>Setting: </bold>Community, Oxfordshire, England.<bold>Participants: </bold>One hundred eighty-two healthy infants.<bold>Interventions: </bold>Participants were randomly assigned to receive vaccination with 0. 5-mL doses of 1 of 2 lots of meningococcal C conjugate vaccine (groups 1 and 2; n=60 in each group) or a hepatitis B control vaccine (group 3; n=62), administered with routine immunizations at 2, 3, and 4 months of age. Approximately half of each group received meningococcal C conjugate vaccine and half received plain meningococcal polysaccharide vaccine (MPS) at 12 months of age.<bold>Main Outcome Measures: </bold>Serum antibodies to meningococcal C polysaccharide, assayed by enzyme-linked immunosorbent assay, and serum bactericidal activity (SBA), at 2, 3, 4, 5, 12, and 13 months of age; local and systemic reactions, recorded for 6 days after each vaccination, compared by intervention group.<bold>Results: </bold>Meningococcal C conjugate vaccine was well tolerated. After 3 doses, children in groups 1 and 2 achieved significantly higher meningococcal C IgG geometric mean concentrations (21 and 17 U/mL, respectively, vs 0.20 U/mL; P<.001) and SBA titers (629 and 420, respectively, vs 4.1; P<. 001) than controls. At 12 months, antibody concentrations had decreased in all groups but remained significantly higher in children vaccinated with meningococcal C conjugate vaccine (SBA, 24 and 16 in groups 1 and 2, respectively, vs 4.2 in group 3; P<.001). Following vaccination with MPS at 12 months of age, SBA in the meningococcal C conjugate vaccine group was significantly higher than in controls (SBA, 789 vs 4.5; P<.001).<bold>Conclusions: </bold>Our data indicate that meningococcal C conjugate vaccine is safe and immunogenic and results in immunologic memory when given with other routinely administered vaccines to infants at 2, 3, and 4 months of age. JAMA. 2000;283:2795-2801
- Publication
JAMA: Journal of the American Medical Association, 2000, Vol 283, Issue 21, p2795
- ISSN
0098-7484
- Publication type
journal article
- DOI
10.1001/jama.283.21.2795